European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

yf_tkr_ACAD · 2026-08-24 · Bullish AI sentiment

$ACAD

SAN DIEGO, August 24, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU).

Read the original at yf_tkr_ACAD ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.